You just read:

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma

News provided by

Janssen Oncology

Dec 04, 2018, 10:30 ET